{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:10:10Z","timestamp":1791897010132,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s15010-022-01933-5","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T10:02:58Z","timestamp":1665050578000},"page":"475-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1117-0470","authenticated-orcid":false,"given":"Victoria","family":"Gavaghan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dela-Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"1933_CR1","unstructured":"Fetroja\u00ae (cefiderocol) [package insert]. Florham Park, NJ: Shionogi Inc.; 2020."},{"key":"1933_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","volume":"79","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG, Golden AR, Zelenistky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs. 2019;79:271\u201389.","journal-title":"Drugs"},{"key":"1933_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17","author":"A Ito","year":"2018","unstructured":"Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.01454-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1933_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomized, open-label, multicenter, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226\u201340.","journal-title":"Lancet Infect Dis"},{"key":"1933_CR5","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomized, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319\u201328.","journal-title":"Lancet Infect Dis"},{"key":"1933_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomized, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21:213\u201325.","journal-title":"Lancet Infect Dis"},{"key":"1933_CR7","unstructured":"Center for Drug Evaluation and Research. (2022). Cefiderocol Injection. U.S. Food and Drug Administration. 6 Jun 2022. https:\/\/www.fda.gov\/drugs\/development-resources\/cefiderocol-injection"},{"key":"1933_CR8","doi-asserted-by":"publisher","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","volume":"3","author":"R Pascale","year":"2021","unstructured":"Pascale R, Pasquini Z, Bartoletti M, et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in ICU during COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist. 2021;3:dlab174.","journal-title":"JAC Antimicrob Resist"},{"key":"1933_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa185","author":"S Zingg","year":"2020","unstructured":"Zingg S, Nicoletti GJ, Kuster S, et al. Cefiderocol for extensively drug-resistant gram-negative bacterial infections: real-world experience from a case series and review of the literature. OFID. 2020. https:\/\/doi.org\/10.1093\/ofid\/ofaa185.","journal-title":"OFID"},{"key":"1933_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/antibiotics10060652","volume":"10","author":"DF Bavaro","year":"2021","unstructured":"Bavaro DF, Belati A, Diella L, et al. Cefiderocol-based combination therapy for \u201cdifficult-to-treat\u201d gram-negative severe infections: real-life case series and future perspectives. Antibiotics (Basel). 2021;10:652.","journal-title":"Antibiotics (Basel)"},{"key":"1933_CR11","doi-asserted-by":"publisher","first-page":"e02142","DOI":"10.1128\/aac.02142-21","volume":"66","author":"M Falcone","year":"2022","unstructured":"Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022;66:e02142-e2221.","journal-title":"Antimicrob Agents Chemother"},{"key":"1933_CR12","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients. Clin Infect Dis. 2021;72:2021\u20134.","journal-title":"Clin Infect Dis"},{"key":"1933_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/ofid\/ofx163.895","volume":"4","author":"M Tsuji","year":"2017","unstructured":"Tsuji M, Hackel M, Echols R, et al. In vitro activity of cefiderocol against globally collected carbapenem-resistant gram-negative bacteria isolated from urinary track source. SIDERO-CR-2014\/2016. OFID. 2017;4:366.","journal-title":"OFID"},{"key":"1933_CR14","doi-asserted-by":"publisher","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","volume":"3","author":"M Meschiari","year":"2021","unstructured":"Meschiari M, Volpi S, Faltoni M, et al. Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections. JAC Antimicrob Resist. 2021;3:dlab188.","journal-title":"JAC Antimicrob Resist"},{"key":"1933_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1013","author":"PD Tamma","year":"2021","unstructured":"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of America guidance on the treatment of AmpC \u03b2-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab1013.","journal-title":"Clin Infect Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01933-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-022-01933-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01933-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:24:11Z","timestamp":1744205051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-022-01933-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1933"],"URL":"https:\/\/doi.org\/10.1007\/s15010-022-01933-5","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Obtained from the AAH Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors gave consent for the submission and publication of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}